[1] BRAY F, LAVERSANNE M, SUNG H, et al.Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. A Cancer Journal for Clinicians, 2024, 4(3): 229-263. [2] National Center for ADR Monitoring, China. National Adverse Drug Reaction Monitoring Report (2021)[EB/OL]. (2022-03-30)[2024-08-05]. https://www.cdr-adr.org.cn/tzgg_home/202203/t20220330_49585.html. [3] ZHOU YY, XU DY, QI Y, et al.Prescription Status of Antitumor Drugs at Chinese Hospitals[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2021, 41(18): 1817-1822. [4] National Health Commission of the People's Republic of China. Notice of the General Office of the National Health Commission on Issuing the Clinical Application Guideline for New Anti-Tumor Drugs (2023 Edition)[EB/OL]. (2024-01-03)[2025-04-30]. http://www.nhc.gov.cn/yzygj/s7659/202401/48be6030a029446c93b852bfd4a5fdf6.shtml. [5] ZHENG RS, CHEN R, HAN BF, et al.Cancer Incidence and Mortality in China, 2022[J]. Chinese Journal of Oncology(中华肿瘤杂志), 2024, 46(3): 221-231. [6] CAO MM, CHEN WQ.Epidemiology of Cancer in China and the Current Status of Prevention and Control[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2019, 46(3): 145-149. [7] HAN B, ZHENG R, ZENG H, et al.Cancer Incidence and Mortality in China, 2022[J]. Journal of the National Cancer Center, 2024, 4(1): 47-53. [8] XIA H, ZHOU C, LUO Z, et al.Apatinib-Induced Hand-Foot Skin Reaction in Chinese Patients with Liver Cancer[J]. Frontiers in Oncology, 2021, 11: 624369. [9] MCLELLAN B, CIARDIELLO F, LACOUTURE M, et al.Regorafenib-Associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Prevention, and Management[J]. Annals of Oncology, 2015, 26(10): 2017-2026. [10] Shanghai Medical Association Dermatology and Venereology Branch, Shanghai Medical Association Tumor Target Molecule Branch. Consensus on the Management of Cutaneous Adverse Reactions to Anti-Tumor Drugs[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2023, 56(10): 907-919. [11] POSTOW MA, SIDLOW R, HELLMANN MD.Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. The New England Journal of Medicine, 2018, 378(2): 158-168. [12] YAXIN D, WENJIE W, MEI C, et al.Cutaneous Adverse Events and Cancer Survival Prognosis with Immune Checkpoint Inhibitor Treatment: a Systematic Review and Meta-Analysis[J]. JAMA Dermatology, 2023, 159(10): 1093-1101. [13] Chinese Medical Association Dermatology and Venereology Branch, Chinese Medical Association Dermatologists Branch, Chinese Geriatrics Society Dermatology Branch. Consensus on Diagnosis and Treatment of Skin Adverse Reactions Related to Immune Checkpoint Inhibitors (2024 Edition)[J]. National Medical Journal of China(中华医学杂志), 2024, 104(20): 1790-1803. [14] GUO HX, CHANG HL, FENG JH.Immune-Associated Toxic Epidermal Necrolysis: a Case Report and Literature Review[J]. Chinese Journal of Cancer Biotherapy(中国肿瘤生物治疗杂志), 2022, 29(11): 1006-1009. [15] HU ZX, DONG HJ, LI CX, et al.Stevens-Johnson Syndrome Induced by Sequentially Using of Furmonertinib after Immune Checkpoint Inhibitors: a Case[J]. China Journal of Leprosy and Skin Diseases(中国麻风皮肤病杂志), 2023, 39(1): 31-34. [16] CHENG MX, CHEN YS, ZHAO YC, et al.One Case of Toxic Epidermal Necrolysis Drug Eruption Caused by Tirellizumab[J]. Herald of Medicine(医药导报), 2022, 41(4): 581-583. [17] SUN Y, YANG J.Multidisciplinary Expert Consensus on Cutaneous Adverse Reactions Induced by Immune Checkpoint Inhibitors (2025 Edition)[J]. Chinese Journal of Clinical Medicine(中国临床医学), 2025, 32(2): 306-321. [18] MAITRY B, NEE MC, SANGEETA SP.Adverse Cutaneous Toxicities by PD-1/PD-L1 Immune Checkpoint Inhibitors: Pathogenesis, Treatment, and Surveillance[J]. Cutaneous and Ocular Toxicology, 2022, 41(1): 73-90. [19] AJ T, JB S, JULIE B, et al.Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology[J]. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20(4): 387-405. [20] ALESSANDRINO F, TIRUMANI S, KRAJEWSKI K, et al.Imaging of Hepatic Toxicity of Systemic Therapy in A Tertiary Cancer Centre: Chemotherapy, Haematopoietic Stem Cell Transplantation, Molecular Targeted Therapies, and Immune Checkpoint Inhibitors[J]. Clinical Radiology, 2017, 72(7): 521-533. [21] GUO YJ, CHEN X, MENG P.Adverse Drug Reaction Reports in 141 Cases of Orally Administered Targeted Anti-Tumor Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(10): 1137-1142, 1147. [22] SUN XL, ZHENG L, LI HS, et al.Research Progress of Chemo-therapy-Related Diarrhea Induced by Molecularly Targeted Anti-Tumor Drugs[J]. China Pharmacy(中国药房), 2024, 35(4): 506-512. [23] MA J, WANG WJ, YU J.Mechanism of Hypertension Induced by Anti-Angiogenesis Targeting Drugs[J]. Advances in Cardiovascular Diseases(心血管病学进展), 2023, 44(9): 841-844, 852. [24] China Hypertension Prevention and Treatment Guidelines Revision Committee, Hypertension Alliance (China), China Association for the Promotion of International Exchanges in Health Care Hypertension Branch, et al. Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 Revision)[J]. Chinese Journal of Hypertension(中华高血压杂志中英文), 2024, 32(7): 603-700. [25] Chinese Society of Clinical Oncology (CSCO) Vascular Targeted Therapy Expert Committee, Chinese Society of Clinical Oncology (CSCO) Non-Small Cell Lung Cancer (NSCLC) Expert Committee, Chinese Society of Clinical Oncology (CSCO) Non-Small Cell Lung Cancer Anticoagulant Therapy Expert Group. Chinese Expert Consensus on Anticoagulant Therapy for Advanced Non-Small Cell Lung Cancer (2022 Edition)[J]. National Medical Journal of China(中华医学杂志), 2022, 102(48): 3819-3835. [26] WEN YP, XIAO HW, SHEN LP, et al.Advances in Risk Factors and Management Strategies of Checkpoint Inhibitor Pneumonitis[J]. Journal of Modern Oncology(现代肿瘤医学), 2023, 31(4): 770-774. [27] Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Common Malignant Tumors(中国临床肿瘤学会(CSCO)常见恶性肿瘤诊疗指南)[M]. Beijing: People's Medical Publishing House, 2023: 1103-1148. [28] THOMPSON AJ, SCHNEIDER JB, BRAHMER J, et al.NCCN Guidelines® Insights: Management of Immunotherapy-Related Toxicities, Version 2, 2024[J]. Journal of the National Comprehensive Cancer Network : JNCCN, 2024, 22(9): 582-592. [29] ZHANG XL, LIU PC, ZHU Z, et al.Expert Consensus on Construction of Pharmacovigilance System in Health Facilities[J]. Chinese Journal of Drug Application and Monitoring(中国药物应用与监测), 2022, 19(3): 135-144. |